As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.
|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Advertisement
Related to this article
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
FDA Pauses Commissioner’s National Priority Voucher Program: Report
3
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
4
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
5